Compare Novartis AG (NVS) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Upwork Inc — how do they compare? Novartis AG trades at $143.11 (market cap $268.57B), while Upwork Inc trades at $8.57 (market cap $1.07B). The key difference: Novartis AG is far larger — about 251× Upwork Inc's market cap, and Novartis AG pays a 3.31% dividend while Upwork Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Upwork Inc for 38 Days on average.
| NVS | UPWK | |
|---|---|---|
Market Cap | $268.57B | $1.07B |
Volume | 1,532,573 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $168.62 | $22.11 |
52-Week Low | $121.80 | $7.84 |
Typical Hold Time | 82 Days | 38 Days |
Enterprise Value | $309.89B | $833.01M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Upwork (UPWK) trades at $8.40, up 0.48% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 EPS of $0.41, beating expectations, but revenue growth has slowed, with 2025 revenue at $787.78 million. Valuation metrics appear attractive with a P/E of 10.77 and P/S of 1.45. Recent news highlights insider sales and a securities fraud investigation, while Bank of America acquired a significant stake.
The outlook is mixed: low valuation and strong profitability margins offer upside, but AI competition and recent insider selling pose risks. Analyst consensus is a Buy with a $9.64 price target, implying potential appreciation, though sentiment is cautious due to growth concerns and legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
